Please assess the completion status of the following clinical trial:

Trial Title: S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed gastric cancer~* Clinical stage : - Borrmann type IV~  * Large Borrmann type III (\>8cm)~ * Locally extensive nodal disease~* No evidence of metastasis~* Patients with tumor lesions which can be easily obtained fresh tumor tissue through repeated biopsies.~* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.~* Age≥ 20 years old.~* Performance status of Eastern Cooperative Oncology Group 0 to 2.~* Adequate organ function.~Exclusion Criteria:~1. metastatic disease~2. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.~3. Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)~4. Pregnant or lactating female~5. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction DCS chemotherapy (Type: EXPERIMENTAL): 1. Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~   * Docetaxel 30 mg/m2 day1, 8~  * Cisplatin 30 mg/m2 day1, 8~2. Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).